


# Washington State Medical Assistance Administration

## Disease Management Program

Alice Lind, RN, MPH

June 2004

# Washington State Medicaid Population



# Why Disease Management?

- Gaps between recommended & actual care
- Increasing costs in health care utilization
- Cost savings guarantee available

# Gaps between recommended and actual care

## Asthma study:


- 30 – 50% had no provider visit in 6 months
- 1/3 with no PCP had ER visits (median 2/6 months, max 24 visits)
- 18% children exposed to smoke at homes
- 33% of adults smoked every day

# Gaps between recommended and actual care

## Diabetes study:

- Fewer than 20% had dilated eye exam in previous year (chart review)
- Only 60% had HgbA1c (chart review)
- Fewer than half had received diabetic education past year (client survey)


# Increasing costs in health care utilization



## Cost savings guarantee available

- Legislative directive to implement DM for “at least three conditions”, improve outcomes and save 5 – 10% of medical expenses.
- Assumption that program implementation is also underwritten by savings in the current fiscal cycle.

# RFP Overview: what we asked for




## IMPROVED:

- Client health
- Client education
- Access to prevention
- Continuity of care
- Coordination with case managers
- Collaboration with medical providers



# RFP Overview: what we asked for



## DECREASED:

- Use of ER
- Hospitalizations
- Overall expenses by 5%

& Inclusion of co-morbid conditions

# Program Description: McKesson

- Four primary conditions: AST, DIA, HF, COPD
  - Manage the “whole” client: co-morbidities and psycho-social issues
  - Supported by 24 x 7 nurse advice line
- Three-level risk stratification, but attempt to contact & directly manage all members

# Program Description: McKesson

- Reinforce national guidelines and provider instructions, with goal of increasing compliance
- Mix of telephonic and face-to-face visits for high-risk/high need clients
- Proprietary clinical application based on national guidelines

# Program Description: Renaissance

- Focus on co-morbid conditions – diabetes, CHF, peripheral vascular disease
- Reduce risk of vascular access complications
- Improve member compliance
- Individual multi-disciplinary treatment plans

# Program Description: Renaissance

- Proprietary clinical information systems
- Risk stratification – 5 acuity levels drive interventions which are both face-to-face and telephonic
- Evidence-based protocols

# Challenges in Implementation



- Centers for Medicare and Medicaid Services (CMS) issues
- Provider issues
- Data sharing and quality
- Shared case management

## Caseload by Condition

Condition	Enrolled	Assessed	Current
Asthma	11,666	5345	2300
Diabetes	11,462	4889	2695
CHF	2568	1200	633
ESRD/CKD			136/4

# Mapping of Washington State Medicaid Referrals Aggregate Level, by County

## Member Count by County





# What are the expectations?

Carry 100% Risk for fees:

- 80% based on cost savings guarantee
- 20% based on improvements in clinical indicators

# Asthma Clinical Indicators

Clinical Indicator	Initial Assessment	6 Months Assessment	12 Months Assessment
<b>Daily Preventative Medications</b>	63% n=4722	75% n=1652	80% n=944
<b>Client has action plan</b>	12% n=5407	24% n=1997	24% n=1408
<b>Flu vaccine</b>	45% n=5407	60% n=1997	65% n=1408
<b>Not a Current Smoker</b>	61% n=4413	63% n=1997	70% n=1222

# Heart Failure Clinical Indicators

Clinical Indicator	Initial Assessment	6 Months Assessment	12 Months Assessment
<b>ACE inhibitor usage</b>	60% n=1247	70% n=535	72% n=358
<b>Weigh daily</b>	32% n=615	70% n=466	64% n=327
<b>Low sodium diet</b>	66% n=1247	67% n=535	69% n=358
<b>Flu vaccine</b>	51% n=1247	60% n=535	66% n=358

# Diabetes Clinical Indicators

Clinical Indicator	Initial Assessment	6 Months Assessment	12 Months Assessment
<b>HbA1c testing rate</b>	40% n=1846	57% n=2476	59% n=1696
<b>Lipid profile</b>	72% n=4986	84% n=2540	88% n=1697
<b>Aspirin/Anti-platelet</b>	41% n=4409	58% n=2164	64% n=1020
<b>Flu vaccine</b>	51% n=4986	67% n=2540	69% n=1697

# Clinical Outcomes: DOQI guidelines for ESRD, Y2Q4

	Clinical Outcome Average	% of Members Achieving Goal	Program Objectives
<b>Albumin</b>	3.75	77%	$\geq 3.5$
<b>KT/V or URR</b>	1.65 74%	93%	$\geq 1.2$ $\geq 65\%$
<b>Ca*PO4</b>	47.88	93%	$\leq 70$
<b>Hemoglobin</b>	12.18	97%	$\geq 10$

# Current DM Program impact (Renaissance Year Two)

- 124 average monthly ESRD members –  
95% enrollment rate
- CKD program in development
- Coordination with McKesson on CKD members
- Other Year 2 Results:
  - Increased fistula placement
  - Decreased hospitalization rate
  - Projected savings above fees for ESRD

# Evaluation of DM Program

Evaluation will include:

- Health status
- Health processes and outcome indicators
- Utilization of medical services
- Client satisfaction
- Continuity of care
- Cost savings

# THANK YOU!

## For more information:

Alice Lind, Care Coordination Manager

Medical Assistance Administration

360-725-1629

E-mail: [lindar@dshs.wa.gov](mailto:lindar@dshs.wa.gov)

On the web: <http://maa.dshs.wa.gov>